There have been major advances in the armamentarium for hepatocellular carcinoma
(HCC) since the last official update of the Barcelona Clinic Liver Cancer prognosis and …

Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related death
worldwide. Risk factors for HCC include chronic hepatitis B and hepatitis C, alcohol …

This guidance document provides an updated approach to the prevention, diagnosis, and
treatment of hepatocellular carcinoma (HCC). The prior American Association for the Study …

The NCCN Guidelines for Hepatobiliary Cancers focus on the screening, diagnosis, staging,
treatment, and management of hepatocellular carcinoma (HCC), gallbladder cancer, and …

Hepatocellular carcinoma is one of the leading causes of cancer related death in the world.
Biannual surveillance for the disease in patients with cirrhosis and in high risk carriers of …

The incidence of hepatocellular carcinoma (HCC) has been rising worldwide over the last
20 years and is expected to increase until 2030 in some countries including the United …

Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-
related death globally. Hepatocellular carcinoma represents about 90% of primary liver …

Hepatocellular carcinoma is a leading cancer worldwide. Its incidence is increasing, and is
closely related to advanced liver disease. Cirrhosis represents the greatest risk factor for this …

Background Transarterial chemoembolisation (TACE) is the standard of care for patients
with intermediate stage hepatocellular carcinoma, while the multikinase inhibitor sorafenib …

The NCCN Guidelines for Hepatobiliary Cancers provide treatment recommendations for
cancers of the liver, gallbladder, and bile ducts. The NCCN Hepatobiliary Cancers Panel …